Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPX-303 in advanced solid tumors
ChiCTR2600135277Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SPX-303 in Nonhematologic neoplasms, colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC) and 6 more (3 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Incidence and types of adverse events, serious adverse events, and dose-limiting toxicities in Part A, Determination of maximum tolerated dose and recommended phase 2 dose in Part A and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SPX-303
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2600135277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135277.